346 related articles for article (PubMed ID: 17108148)
1. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
2. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
[TBL] [Abstract][Full Text] [Related]
3. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
4. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
[TBL] [Abstract][Full Text] [Related]
6. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of Afro-Caribbean population with prostate cancer].
Veronique-Baudin J; Dieye M; Kouyoumdjian JC; Vacheron F; Draganescu C; Azaloux H
Prog Urol; 2006 Jun; 16(3):303-10. PubMed ID: 16821341
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
8. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
10. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
Lindström S; Zheng SL; Wiklund F; Jonsson BA; Adami HO; Bälter KA; Brookes AJ; Sun J; Chang BL; Liu W; Li G; Isaacs WB; Adolfsson J; Grönberg H; Xu J
Prostate; 2006 Dec; 66(16):1729-43. PubMed ID: 16998812
[TBL] [Abstract][Full Text] [Related]
11. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
12. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
Modugno F; Weissfeld JL; Trump DL; Zmuda JM; Shea P; Cauley JA; Ferrell RE
Clin Cancer Res; 2001 Oct; 7(10):3092-6. PubMed ID: 11595700
[TBL] [Abstract][Full Text] [Related]
13. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
Hedelin M; Bälter KA; Chang ET; Bellocco R; Klint A; Johansson JE; Wiklund F; Thellenberg-Karlsson C; Adami HO; Grönberg H
Prostate; 2006 Oct; 66(14):1512-20. PubMed ID: 16921512
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
[TBL] [Abstract][Full Text] [Related]
16. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
Liu JH; Li HW; Tong M; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
[TBL] [Abstract][Full Text] [Related]
18. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
19. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
[TBL] [Abstract][Full Text] [Related]
20. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
